Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis

European Journal of Health Economics

Volumn 11, Issue 1, 2010, Pages 67-76

  Punekar, Yogesh Suresh ^a   Hawkins, Neil ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ICON PLC   (United Kingdom)

Author keywords

Acute; Cost effectiveness; Infliximab; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HYDROCORTISONE; INFLIXIMAB; PLACEBO; PREDNISOLONE;

ARTICLE; COLON RESECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ULCERATIVE COLITIS;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BAYES THEOREM; COLECTOMY; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; CYCLOSPORINE; DECISION SUPPORT TECHNIQUES; GASTROINTESTINAL AGENTS; GREAT BRITAIN; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, ECONOMIC; MODELS, STATISTICAL; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 76649143064     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0199-5     Document Type: Article

References (23)

1. MJ Carter AJ Lobo SP Travis 2004 Guidelines for the management of inflammatory bowel disease in adults Gut 53 5 V1 V16 10.1136/gut.2004.043372 (Pubitemid 39120096)
2. G Jarnerot P Rolny H Sandberg-Gertzen 1985 Intensive intravenous treatment of ulcerative colitis Gastroenterology 89 5 1005 1013
3. SC Truelove DP Jewell 1974 Intensive intravenous regimen for severe attacks of ulcerative colitis Lancet 1 7866 1067 1070 10.1016/S0140-6736(74) 90552-2
4. Leiper, K., Lowe, D., Driscoll, R., et al.: UK IBD audit 2006: National results for the organisation and process of IBD care in the UK. Published 2007; available at http://www.rcplondon.ac.uk/college/ceeu/ceeu-uk-ibd-audit-2006.pdf
5. S Travis E Trange A Lemann, et al. 2008 European evidence based consensus on the diagnosis and management of ulcerative colitis: current management J. Crohn's Colitis 2 24 62 10.1016/j.crohns.2007.11.002 (Pubitemid 351179488)
6. J Arts G D'Haens M Zeegers, et al. 2004 Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis Inflam. Bowel Dis. 10 73 78 10.1097/00054725-200403000-00002 (Pubitemid 38332164)
7. WJ Sandborn 1995 A critical review of cyclosporine therapy in inflammatory bowel disease Inflam. Bowel Dis. 1 48 63 10.1002/ibd.3780010107
8. G Jarnerot E Hertervig I Friis-liby, et al. 2005 Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized placebo controlled study Gastroenterology 128 1805 1811 10.1053/j.gastro.2005.03.003 (Pubitemid 40824691)
9. BE Sands WJ Tremaine WJ Sandborn PJ Rutgeerts SB Hanauer L Mayer SR Targan DK Podolsky 2001 Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study Inflam. Bowel Dis. 7 2 83 88 10.1097/00054725-200105000-00001
10. HH Tsai YS Punekar J Morris, et al. 2008 A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis Aliment. Pharmacol. Ther. 15;28 10 1230 1239 10.1111/j.1365-2036.2008.03839.x
11. G D'Haens L Lemmens K Geboes, et al. 2001 Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis Gastroenterology 120 6 1323 1329 10.1053/gast.2001.23983
12. S Lichtiger DH Present A Kornbluth, et al. 1994 Cyclosporine in severe ulcerative colitis refractory to steroid therapy N. Engl. J. Med. 330 26 1841 1845 10.1056/NEJM199406303302601 (Pubitemid 24188135)
13. A Ades N Welton D Caldwell, et al. 2008 Multiparameter evidence synthesis in epidemiology and medical decision-making J. Health Serv. Res. Policy 13 Suppl 3 12 22 10.1258/jhsrp.2008.008020
14. DJ Lunn A Thomas N Best D Spiegelhalter 2000 WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility Stat. Comput. 10 325 337 10.1023/A:1008929526011
15. Reference costs 2006/07: National schedule of reference costs. Department of Health. January 2008
16. A Woehl B Hawthorne C Morgan Y Punekar P McEwan 2007 The epidemiology and healthcare resource use in patients with Crohn's disease: a population based UK study Value Health 10 6 A355
17. P Dolan 1997 Modeling valuations for EuroQol health states Med. Care 35 11 1095 1108 10.1097/00005650-199711000-00002
18. RS Walmsley RCS Ayres RE Pounder RN Allan 1998 A simple clinical colitis activity index Gut 43 10 29 32
19. K Arseneau S Sultan D Provenzale, et al. 2006 Do patient preferences influence decisions on treatment for patients with steroid refractory ulcerative colitis? Clin. Gastroenterol. Hepatol. 4 9 1135 1142 10.1016/j.cgh.2006.05.003 (Pubitemid 44311640)
20. National Institute of Health and Clinical Excellence (NICE): Guide to the Methods of Technology Appraisal (reference NO515). NICE, London, (2004), http://www.nice.org.uk/niceMedia/pdf/TAP-Methods.pdf
21. A Kohn M Daperno A Armuzzi, et al. 2007 Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up Aliment. Pharmacol. Ther. 26 5 747 756
22. National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Psoriasis. London: Technology Appraisal Guidance 134, January (2008), http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Guidelines/NICE- guidance-on-the-use-of-infliximab-for-the-treatment-of-psoriasis/
23. Laharie, D.: A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF). Clinicaltrials.gov identifier-NCT00542152, http:// clinicaltrials.gov/ct2/show/NCT00542152